Cutler Group LLC CA boosted its holdings in Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) by 1,685.7% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,000 shares of the biotechnology company’s stock after purchasing an additional 944 shares during the quarter. Cutler Group LLC CA’s holdings in Blueprint Medicines were worth $50,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in the business. Pinebridge Investments L.P. bought a new stake in shares of Blueprint Medicines in the 2nd quarter worth $46,000. Lazard Asset Management LLC bought a new stake in Blueprint Medicines during the fourth quarter valued at approximately $57,000. Dark Forest Capital Management LP purchased a new stake in shares of Blueprint Medicines in the 1st quarter worth $63,000. Steward Partners Investment Advisory LLC increased its position in Blueprint Medicines by 24.9% in the first quarter. Steward Partners Investment Advisory LLC now owns 1,682 shares of the biotechnology company’s stock worth $76,000 after buying an additional 335 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its stake in Blueprint Medicines by 95.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 757 shares during the period.
Wall Street Analyst Weigh In
A number of equities analysts have recently weighed in on the company. Raymond James upped their price objective on Blueprint Medicines from $85.00 to $100.00 and gave the stock a “strong-buy” rating in a research note on Friday, December 22nd. Stifel Nicolaus upped their price target on shares of Blueprint Medicines from $95.00 to $97.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. Barclays raised their price objective on Blueprint Medicines from $46.00 to $58.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. Morgan Stanley lifted their price target on shares of Blueprint Medicines from $59.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, October 27th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Blueprint Medicines in a research report on Monday, December 11th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $81.00.
In other Blueprint Medicines news, insider Christopher K. Murray sold 600 shares of Blueprint Medicines stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $71.43, for a total transaction of $42,858.00. Following the completion of the sale, the insider now directly owns 24,495 shares in the company, valued at approximately $1,749,677.85. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, insider Christopher K. Murray sold 600 shares of Blueprint Medicines stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $71.43, for a total transaction of $42,858.00. Following the completion of the transaction, the insider now directly owns 24,495 shares of the company’s stock, valued at approximately $1,749,677.85. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 25,000 shares of the stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $81.91, for a total transaction of $2,047,750.00. Following the sale, the director now directly owns 176,050 shares in the company, valued at $14,420,255.50. The disclosure for this sale can be found here. Insiders have sold 51,314 shares of company stock valued at $3,895,268 over the last ninety days. 3.88% of the stock is currently owned by insiders.
Blueprint Medicines Stock Performance
Shares of Blueprint Medicines stock opened at $74.20 on Thursday. The company has a 50 day moving average price of $82.57 and a 200 day moving average price of $63.88. The firm has a market capitalization of $4.51 billion, a P/E ratio of -8.07 and a beta of 0.61. Blueprint Medicines Co. has a 52 week low of $37.82 and a 52 week high of $94.00. The company has a quick ratio of 4.01, a current ratio of 4.09 and a debt-to-equity ratio of 1.03.
Blueprint Medicines Company Profile
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib.
- Five stocks we like better than Blueprint Medicines
- What is the Euro STOXX 50 Index?
- What are specialty REITs? How to invest in them
- How and Why to Invest in Oil Stocks
- Miso Robotics stock: Is an IPO coming soon?
- What is a buyback in stocks? A comprehensive guide for investors
- Insiders are selling these hot stocks on track for higher prices
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.